Below are the most recent publications written about "Partial Thromboplastin Time" by people in Profiles.
-
Volod O, Rollins-Raval M, Goodwin AJ, Higgins RA, Long T, Chandler WL, Harris NS, Pham HP, Isom JA, Moser K, Olson JD, Smock KJ, VanSandt A, Wool G, Chen D. Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban. Arch Pathol Lab Med. 2022 01 02; 146(2):145-153.
-
Biemond BJ, Tombak A, Kilinc Y, Al-Khabori M, Abboud M, Nafea M, Inati A, Wali Y, Kristensen J, Kowalski J, Donnelly E, Ohd J. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2021 May; 8(5):e334-e343.
-
Sasso R, Rockey DC. Controversies in anticoagulation therapy in patients with cirrhosis. Curr Opin Gastroenterol. 2019 05; 35(3):161-167.
-
Floroff CK, Palm NM, Steinberg DH, Powers ER, Wiggins BS. Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications. Pharmacotherapy. 2017 Apr; 37(4):393-400.
-
Thompson MH, Wilson SH, Toussaint BL, Jordan CL, Hayes GL, McKinzie BP, Wolf BJ, Field LC. Effect of Subcutaneous Unfractionated Heparin Prophylaxis on Activated Partial Thromboplastin Time: A Retrospective Evaluation. J Clin Anesth. 2016 Sep; 33:346-50.
-
Cooper T, White CL, Taber D, Uber WE, Kokko H, Mazur J. Safety and effectiveness outcomes of an inpatient collaborative drug therapy management service for direct thrombin inhibitors. Am J Health Syst Pharm. 2012 Nov 15; 69(22):1993-8.
-
Sievert A, Uber W, Laws S, Cochran J. Improvement in long-term ECMO by detailed monitoring of anticoagulation: a case report. Perfusion. 2011 Jan; 26(1):59-64.
-
Anderegg BA, Baillie GM, Uber WE, Chavin KD, Lin A, Baliga PK, Lazarchick J. Use of bivalirudin to prevent thrombosis following orthotopic liver transplantation in a patient with Budd-Chiari syndrome and a history of heparin-induced thrombocytopenia. Ann Clin Lab Sci. 2008; 38(3):277-82.
-
McGlasson DL, Harroff HH, Sutton J, Dick E, Elston DM. Cutaneous and systemic effects of varying doses of brown recluse spider venom in a rabbit model. Clin Lab Sci. 2007; 20(2):99-105.
-
Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, Lin M, Myles SK, Melloni C, Harrington RA, Alexander JH, Becker RC, Rusconi CP. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation. 2006 Dec 05; 114(23):2490-7.